307 related articles for article (PubMed ID: 23238297)
1. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.
Li L; Luo Z; Yu H; Feng X; Wang P; Chen J; Pu Y; Zhao Y; He H; Zhong J; Liu D; Zhu Z
Diabetes; 2013 Mar; 62(3):762-74. PubMed ID: 23238297
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
Shiota A; Shimabukuro M; Fukuda D; Soeki T; Sato H; Uematsu E; Hirata Y; Kurobe H; Maeda N; Sakaue H; Masuzaki H; Shimomura I; Sata M
Cardiovasc Diabetol; 2012 Nov; 11():139. PubMed ID: 23137106
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench.
Chang WT; Cheng JT; Chen ZC
Cardiovasc Diabetol; 2016 Aug; 15(1):113. PubMed ID: 27519769
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway.
Feng X; Luo Z; Ma L; Ma S; Yang D; Zhao Z; Yan Z; He H; Cao T; Liu D; Zhu Z
J Cell Mol Med; 2011 Jul; 15(7):1572-81. PubMed ID: 20477906
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
8. Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.
Kobayashi T; Akiyama Y; Akiyama N; Katoh H; Yamamoto S; Funatsuki K; Yanagimoto T; Notoya M; Asakura K; Shinosaki T; Hanasaki K
Eur J Pharmacol; 2010 Dec; 649(1-3):23-8. PubMed ID: 20826135
[TBL] [Abstract][Full Text] [Related]
9. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta.
Krämer DK; Al-Khalili L; Perrini S; Skogsberg J; Wretenberg P; Kannisto K; Wallberg-Henriksson H; Ehrenborg E; Zierath JR; Krook A
Diabetes; 2005 Apr; 54(4):1157-63. PubMed ID: 15793256
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
15. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
Younis F; Oron Y; Limor R; Stern N; Rosenthal T
Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
18. [Non-agonist inhibitors of Cdk5-dependent phosphorylation of PPAR as insulin sensitizers in the future?].
Merk D; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2012 May; 41(3):182-3. PubMed ID: 22844662
[No Abstract] [Full Text] [Related]
19. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
20. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
